ABVC BioPharma Toekomstige groei
Future criteriumcontroles 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for ABVC BioPharma.
Belangrijke informatie
n/a
Groei van de winst
n/a
Groei van de winst per aandeel
Biotechs winstgroei | 27.1% |
Inkomstengroei | n/a |
Toekomstig rendement op eigen vermogen | n/a |
Dekking van analisten | None |
Laatst bijgewerkt | n/a |
Recente toekomstige groei-updates
Geen updates
Recent updates
ABVC BioPharma (NASDAQ:ABVC) Is Carrying A Fair Bit Of Debt
Mar 13Australian ethics committee approves ABVC's phase 2 study plan for its eye-gel substitute
Oct 05ABVC Biopharma rises on clinical update from Phase 2 trial of ADHD drug
Sep 23ABVC BioPharma (NASDAQ:ABVC) Has Debt But No Earnings; Should You Worry?
Aug 18ABVC BioPharma GAAP EPS of -$0.06 beats by $0.07, revenue of $0.31M beats by $0.3M
Aug 17ABVC Biopharma rises 18% on acceleration of ADHD drug Phase 2 trial
Jul 13Thai ethics committee approves ABVC's phase 2 study protocol for its eye-gel substitute
Jun 30Is ABVC BioPharma (NASDAQ:ABVC) Using Too Much Debt?
Apr 04Is ABVC BioPharma (NASDAQ:ABVC) A Risky Investment?
Dec 09Is ABVC BioPharma (NASDAQ:ABVC) A Risky Investment?
Aug 05In dit gedeelte presenteren we gewoonlijk prognoses voor de omzet- en winstgroei op basis van de consensusramingen van professionele analisten om beleggers te helpen begrijpen in hoeverre het bedrijf in staat is winst te genereren. Maar omdat ABVC BioPharma onvoldoende gegevens uit het verleden heeft verstrekt en geen analistenprognose heeft, kan de toekomstige winst niet betrouwbaar worden berekend door gegevens uit het verleden te extrapoleren of analistenprognoses te gebruiken.
Dit is een vrij zeldzame situatie, aangezien 97% van de bedrijven die worden gedekt door SimplyWall St wel financiële gegevens uit het verleden hebben.
Winst- en omzetgroeiprognoses
Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
---|---|---|---|---|---|
6/30/2024 | 0 | -11 | -3 | -3 | N/A |
3/31/2024 | 0 | -13 | -3 | -3 | N/A |
12/31/2023 | 0 | -11 | -4 | -4 | N/A |
9/30/2023 | 1 | -12 | -4 | -4 | N/A |
6/30/2023 | 1 | -13 | -3 | -3 | N/A |
3/31/2023 | 1 | -12 | -6 | -6 | N/A |
12/31/2022 | 1 | -16 | -8 | -7 | N/A |
9/30/2022 | 0 | -19 | -10 | -9 | N/A |
6/30/2022 | 0 | -18 | -11 | -11 | N/A |
3/31/2022 | 0 | -18 | -9 | -9 | N/A |
12/31/2021 | 0 | -13 | -8 | -8 | N/A |
9/30/2021 | 0 | -10 | -7 | -7 | N/A |
6/30/2021 | 0 | -10 | -5 | -5 | N/A |
3/31/2021 | 1 | -10 | -5 | -5 | N/A |
12/31/2020 | 0 | -10 | -5 | -5 | N/A |
9/30/2020 | 1 | -6 | -4 | -4 | N/A |
6/30/2020 | 1 | -5 | -4 | -4 | N/A |
3/31/2020 | 1 | -4 | -3 | -3 | N/A |
12/31/2019 | 1 | -4 | -3 | -3 | N/A |
9/30/2019 | 1 | -6 | -1 | -1 | N/A |
6/30/2019 | 0 | -6 | -1 | -1 | N/A |
3/31/2019 | 0 | -6 | -1 | -1 | N/A |
12/31/2018 | 0 | -6 | -1 | -1 | N/A |
9/30/2018 | 0 | -2 | -1 | -1 | N/A |
6/30/2018 | 0 | -5 | -1 | -1 | N/A |
3/31/2018 | N/A | -5 | N/A | -1 | N/A |
12/31/2017 | N/A | -4 | N/A | -1 | N/A |
9/30/2017 | N/A | -4 | N/A | -2 | N/A |
6/30/2017 | N/A | -1 | N/A | -1 | N/A |
3/31/2017 | N/A | -1 | N/A | -4 | N/A |
12/31/2016 | N/A | -8 | N/A | -3 | N/A |
9/30/2016 | N/A | -11 | N/A | -3 | N/A |
12/31/2015 | N/A | -5 | N/A | -1 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: Insufficient data to determine if ABVC's forecast earnings growth is above the savings rate (2.5%).
Winst versus markt: Insufficient data to determine if ABVC's earnings are forecast to grow faster than the US market
Hoge groeiwinsten: Insufficient data to determine if ABVC's earnings are expected to grow significantly over the next 3 years.
Omzet versus markt: Insufficient data to determine if ABVC's revenue is forecast to grow faster than the US market.
Hoge groei-inkomsten: Insufficient data to determine if ABVC's revenue is forecast to grow faster than 20% per year.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Insufficient data to determine if ABVC's Return on Equity is forecast to be high in 3 years time